KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Shares Outstanding (Diluted Average) (2018 - 2025)

Historic Shares Outstanding (Diluted Average) for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $29.1 million.

  • Castle Biosciences' Shares Outstanding (Diluted Average) fell 111.56% to $29.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.1 million, marking a year-over-year decrease of 111.56%. This contributed to the annual value of $29.3 million for FY2024, which is 915.23% up from last year.
  • Latest data reveals that Castle Biosciences reported Shares Outstanding (Diluted Average) of $29.1 million as of Q3 2025, which was down 111.56% from $29.5 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Shares Outstanding (Diluted Average) registered a high of $29.5 million during Q2 2025, and its lowest value of $24.9 million during Q1 2021.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $27.0 million, with a median of $26.7 million in 2023.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first skyrocketed by 4301.76% in 2021, then tumbled by 111.56% in 2025.
  • Castle Biosciences' Shares Outstanding (Diluted Average) (Quarter) stood at $25.1 million in 2021, then grew by 3.65% to $26.1 million in 2022, then grew by 2.87% to $26.8 million in 2023, then grew by 9.15% to $29.3 million in 2024, then decreased by 0.62% to $29.1 million in 2025.
  • Its last three reported values are $29.1 million in Q3 2025, $29.5 million for Q2 2025, and $28.6 million during Q1 2025.